Dr Paolo Gallipoli

Paolo Gallipoli

Clinical Senior Lecturer

Haematology
Queen Mary University of London
www.bartscancer.london/staff/dr-paolo-gallipoli/

Research

Acute myeloid leukaemia, Biology, Metabolism, Therapy

Cancer Models

Interests

We use in vitro models to study the biology and therapy of acute myeloid leukaemia. We always strive to make our models more relevant. For example we have now developed coculture systems to grow leukaemia cells with several different stromal cells and are able to show differences in the leukaemia cell behaviour which are likely more reflective of what happens in vivo

Publications

solid heart iconPublications of specific relevance to Predictive in vitro Models

2025

Analysis of volatile organic compounds in exhaled breath of blood cancer patients identifies products of lipid peroxidation as biomarkers for lymphoma detection
Stiekema LCA, Chou H, Craster A, Wrench B, Bianchi K, Gallipoli P, Davies JK, Gribben JG et al.
Hemasphere, Wiley vol. 9 (7) 
01-07-2025
WNK1 signalling regulates amino acid transport and mTORC1 activity to sustain acute myeloid leukaemia growth

Nature Communications, Springer Nature vol. 16 (1) 
27-05-2025
Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities

Leukemia, Springer Nature vol. 39 (8), 1814-1823.  
22-05-2025
Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis
Gozdecka M, Dudek M, Wen S, Gu M, Stopforth RJ, Rak J, Damaskou A, Grice GL et al.
Nature, Springer Nature vol. 642 (8067), 431-441.  
16-04-2025
Acute myeloid leukaemia
Beinortas T, Gallipoli P
In Hoffbrand's Postgraduate Haematology, Wiley 605-629.  
04-04-2025
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation
Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M et al.
Blood, American Society of Hematology vol. 145 (7), 748-764.  
13-02-2025

2024

A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones
Sánchez-Lanzas R, Barclay J, Hardas A, Kalampalika F, Jiménez-Pompa A, Gallipoli P, Ganuza M
Leukemia, Springer Nature vol. 39 (2), 460-472.  
13-11-2024
Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation
Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M et al.
Blood, American Society of Hematology vol. 144 (Supplement 1) 
05-11-2024
Specific Bone Marrow Niche Components Determine Degree of Protection from Gilteritinib Induced Differentiation Response in FLT3-ITD AML
James SC, Atkinson S, Burt R, Lo Celso C
Blood, American Society of Hematology vol. 144 (Supplement 1), 4152-4152.  
05-11-2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Othman J, Hwang A, Brodermann M, Abdallah I, McCloskey K, Gallipoli P, Clarke G, Dang R et al.
Blood Advances, American Society of Hematology vol. 8 (21), 5590-5597.  
25-10-2024
Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia
Borek WE, Nobre L, Pedicona SF, Campbell AE, Christopher JA, Nawaz N, Perkins DN, Moreno-Cardoso P et al.
Ebiomedicine, Elsevier vol. 108 
17-09-2024
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, Rees D, Byrne J et al.
Leukemia, Springer Nature vol. 38 (11), 2443-2455.  
17-09-2024
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation
Dembitz V, Lawson H, Burt R, Natani S, Philippe C, James SC, Atkinson S, Durko J et al.
Leukemia, Springer Science and Business Media Llc vol. 38 (11), 2395-2409.  
26-08-2024
Multi-drug algorithm to accurately predict best first-line treatments in newly-diagnosed acute myeloid leukemia (AML).
Rodriguez Cutillas P, Borek WE, Christopher JA, Nobre LV, Campbell A, Kelsall J, Pedicona F, Nawaz N et al.
Journal of Clinical Oncology, American Society of Clinical Oncology (Asco) vol. 42 (16_suppl), 6525-6525.  
29-05-2024
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, Mehta P, Yassin H et al.
Blood Neoplasia, Elsevier vol. 1 (3) 
23-05-2024
Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy
Robertson HF, Milojkovic D, Butt N, Byrne J, Claudiani S, Copland M, Gallipoli P, Innes AJ et al.
British Journal of Haematology, Wiley vol. 205 (3), 947-955.  
02-05-2024
The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia
Lawson H, Holt-Martyn JP, Dembitz V, Kabayama Y, Wang LM, Bellani A, Atwal S, Saffoon N et al.
Nature Cancer, Springer Nature vol. 5 (6), 916-937.  
18-04-2024
Immunodeficient NBSGW mouse strain allows chemotherapy modeling in AML patient‐derived xenografts
Dembitz V, Durko J, Campos J, James SC, Lawson H, Kranc KR, Gallipoli P
Hemasphere, Wiley vol. 8 (1) 
01-01-2024

2023

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)
Milojkovic D, Blijlevens N, Kwong Y-L, Zaidi U, Castagnetti F, Gallipoli P, Miggiano MC, Westerweel PE et al.
Blood, American Society of Hematology vol. 142 (Supplement 1) 
02-11-2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy
Othman J, Tiong IS, O'Nions J, Dennis M, Mokretar K, Ivey A, Austin MJ, Latif A-L et al.
Blood, American Society of Hematology vol. 143 (4), 336-341.  
30-08-2023
SCD inhibition preferentially eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy
Dembitz V, Lawson H, Burt R, Philippe C, James SC, Atkinson S, Durko J, Wang LM et al.
In Cold Spring Harbor Laboratory 
05-08-2023
S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT‐POSITIVE ACUTE MYELOID LEUKAEMIA
Dokal A, Borek WE, Nobre L, Pedicona SF, Wrench B, Gallipoli P, Arruda A, Campbell AE et al.
Hemasphere, Wiley vol. 7 (Suppl) 
01-08-2023
O20 TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS
Philippe C, Mian S, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D et al.
Leukemia Research, Elsevier vol. 128 
01-05-2023
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death
Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS et al.
Nature Communications, Springer Nature vol. 14 (1) 
14-04-2023
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia
Fernando F, Innes AJ, Claudiani S, Pryce A, Hayden C, Byrne J, Gallipoli P, Copland M et al.
Bone Marrow Transplantation, Springer Nature vol. 58 (7), 826-828.  
04-04-2023
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in FLT3-Mutant Leukemia
Sabatier M, Birsen R, Lauture L, Mouche S, Angelino P, Dehairs J, Goupille L, Boussaid I et al.
Cancer Discovery, American Association For Cancer Research (Aacr) vol. 13 (7), 1720-1747.  
03-04-2023
Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia
Mian SA, Philippe C, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D et al.
Science Translational Medicine, American Association For The Advancement of Science (Aaas) vol. 15 (685), eabn5135-eabn5135.  
01-03-2023

2022

Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia
Dembitz V, Lawson H, Philippe C, Burt RJ, James S, Magee ASM, Woodley K, Durko J et al.
Blood, American Society of Hematology vol. 140 (Supplement 1), 3058-3060.  
15-11-2022
Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML
Lawson H, Holt-Martyn J, Dembitz V, Durko J, Kabayama Y, Wang L, Van De Lagemaat L, Dubusse L et al.
Blood, American Society of Hematology vol. 140 (Supplement 1), 8731-8732.  
15-11-2022
Real-World Experience of Asciminib: Factors Associated with Response
Innes AJ, Hayden C, Orovboni V, Rees D, Claudiani S, Fernando F, Khan A, Byrne J et al.
Blood, American Society of Hematology vol. 140 (Supplement 1), 6796-6797.  
15-11-2022
Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy
Othman J, Tiong IS, Mokretar K, Ivey A, Austin MJ, Latif A-L, Crawley C, Amer M et al.
Blood, American Society of Hematology vol. 140 (Supplement 1), 2033-2035.  
15-11-2022
AML gets upSET when its dietary needs are unMet
Gallipoli P
Blood, American Society of Hematology vol. 140 (19), 2003-2004.  
10-11-2022
A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies
Dawson MA, Borthakur G, Huntly B, Karadimitris A, Alegre A, Chaidos A, Vogl DT, Pollyea DA et al.
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 29 (4), 711-722.  
09-11-2022
P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE
Innes A, Orovboni V, Claudiani S, Fernando F, Khan A, Byrne J, Gallipoli P, Copland M et al.
Hemasphere, Wiley vol. 6, 601-602.  
01-06-2022
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia
Gallipoli P, Clark RE, Byrne J, Apperley JF, Milojkovic D, Foroni L, Goldman JM, O’Brien S
British Journal of Haematology, Wiley vol. 196 (6), e55-e57.  
06-01-2022

2021

Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia
Mian S, Philippe C, Maniati E, Bergot T, Piganeau M, Di Bella D, Morales V, Finch A et al.
Blood, American Society of Hematology vol. 138 (Supplement 1) 
05-11-2021
Mannose Metabolism Is a Metabolic Vulnerability Unveiled By Standard and Novel Therapies in Acute Myeloid Leukemia
Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Tzelepis K, Philippe C, Rattigan K, Asby R et al.
Blood, American Society of Hematology vol. 138 (Supplement 1) 
05-11-2021
Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service
Othman J, Afzal U, Amofa R, Austin MJ, Bashford A, Belsham E, Byrne J, Coats T et al.
Blood, American Society of Hematology vol. 138 (Supplement 1) 
05-11-2021
Venetoclax with Azacitidine or Low Dose Cytarabine As an Alternative to Intensive Chemotherapy in Fit Adults during the COVID19 Pandemic: Real World Data from the UK National Health Service
Othman J, Amer M, Amofa R, Anderson L, Austin MJ, Bashford A, Belsham E, Boot J et al.
Blood, American Society of Hematology vol. 138 (Supplement 1) 
05-11-2021
Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression
Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D et al.
Nature Genetics, Springer Nature vol. 53 (10), 1443-1455.  
23-09-2021
The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia
Dembitz V, Gallipoli P
Frontiers in Oncology, Frontiers vol. 11 
19-05-2021
Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome
Hughes CFM, Gallipoli P, Agarwal R
Pathology, Elsevier 
04-03-2021

2020

Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy
Forte D, García-Fernández M, Sánchez-Aguilera A, Stavropoulou V, Fielding C, Martín-Pérez D, López JA, Costa ASH et al.
Cell Metabolism, Elsevier vol. 32 (5), 829-843.e9.  
22-09-2020
Does Outcome/Survival of Patients With Myelodysplastic Syndromes Should Be Predicted by Reduced Levels of ADAMTS-13? Results From a Pilot Study
Castelli R, Bergamaschini L, Teatini T, Cilumbriello L, Schiavon R, Gallipoli P, Deliliers GL
Clinical Lymphoma Myeloma & Leukemia, Elsevier vol. 20 (8), e461-e467.  
31-01-2020
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P et al.
Leukemia, Springer Nature vol. 34 (7), 1775-1786.  
10-01-2020

2019

Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies
Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P et al.
Blood, American Society of Hematology vol. 134 (24), 2195-2208.  
12-12-2019
Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)
Claudiani S, Metelli S, Kamvar R, Szydlo R, Khan A, Bulley SJ, Horne GA, Rothwell K et al.
Blood, American Society of Hematology vol. 134 (Supplement_1) 
13-11-2019
Mutational Synergy Coordinately Remodels Chromatin Accessibility, Enhancer Landscape and 3-Dimensional DNA Topology to Alter Gene Expression during Leukemia Induction
Yun H, Vohra S, Mupo A, Giotopoulos G, Sasca D, Horton SJ, Agrawal-Singh S, Basheer F et al.
 
13-11-2019
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L et al.
Journal of Experimental Medicine, Rockefeller University Press vol. 216 (4), 966-981.  
19-03-2019
Histone modifiers are oxygen sensors
Gallipoli P, Huntly BJP
Science, American Association For The Advancement of Science (Aaas) vol. 363 (6432), 1148-1149.  
15-03-2019
Prognostic Models Turn the Heat(IT)up on FLT3ITD-Mutated AML
Gallipoli P, Huntly BJP
Clinical Cancer Research, American Association For Cancer Research (Aacr) vol. 25 (2), 460-462.  
15-01-2019

2018

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4
Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu W-H, Gozdecka M, Metzakopian E et al.
Nature Communications, Springer Nature vol. 9 (1) 
19-12-2018
A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)
Dickinson M, Kamdar M, Huntly BJP, De Larrea CF, Cordoba R, Mateos M-V, Alegre A, Kim W-S et al.
 
29-11-2018
Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation
Castelli R, Gallipoli P, Teatini T, Deliliers GL
Journal of Thrombosis and Thrombolysis, Springer Nature vol. 47 (1), 155-156.  
26-11-2018
JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients
Gallipoli P
Leukemia Research, Elsevier vol. 75, 71-72.  
24-10-2018
Glutaminolysis is a metabolic dependency in FLT3ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition
Gallipoli P, Giotopoulos G, Tzelepis K, Costa ASH, Vohra S, Medina-Perez P, Basheer F, Marando L et al.
Blood, American Society of Hematology vol. 131 (15), 1639-1653.  
20-02-2018

2017

High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation
Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L
Journal of Thrombosis and Thrombolysis, Springer Nature vol. 45 (1), 106-113.  
11-10-2017
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors
Horton SJ, Giotopoulos G, Yun H, Vohra S, Sheppard O, Bashford-Rogers R, Rashid M, Clipson A et al.
 
21-08-2017
Novel epigenetic therapies in hematological malignancies: Current status and beyond
Gallipoli P, Huntly BJP
Seminars in Cancer Biology, Elsevier vol. 51, 198-210.  
04-08-2017
Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia
Gallipoli P, Costa ASH, Vohra S, Castro C, Griffin J, Frezza C
 
01-02-2017
METABOLIC ADAPTATIONS TO TARGETED THERAPY IN FLT3 MUTATED ACUTE MYELOID LEUKAEMIA
Gallipoli P, Costa AS, Tzelepis K, Giotopoulos G, Vohra S, Frezza C
 
01-01-2017

2016

CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG et al.
Blood 
28-10-2016
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V et al.
Cell Reports, Elsevier vol. 17 (4), 1193-1205.  
01-10-2016
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
Scott MT, Korfi K, Saffrey P, Hopcroft LE, Kinstrie R, Pellicano F, Guenther C, Gallipoli P et al.
Cancer Discovery, American Association For Cancer Research vol. 6 (11), 1248-1257.  
14-09-2016
Laboratory and clinical risk assessment to treat myelodysplatic syndromes
Gidaro A, Deliliers GL, Gallipoli P, Arquati M, Wu MA, Castelli R
Clinical Chemistry and Laboratory Medicine, De Gruyter vol. 54 (9), 1411-1426.  
14-01-2016

2015

Salvage Therapy with Bortezomib and Dexamethasone in Elderly Patients with Relapsed Refractory Multiple Myeloma
Castelli R, Gallipoli P, Gidaro A, Maddalena W
 
03-12-2015
Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma
Castelli R, Pantaleo G, Gallipoli P, Gidaro A, Arquati M, Wu MA, Deliliers GL
Anti-Cancer Drugs, Wolters Kluwer vol. 26 (10), 1078-1082.  
01-11-2015
A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression
Giotopoulos G, van der Weyden L, Osaki H, Rust AG, Gallipoli P, Meduri E, Horton SJ, Chan W-I et al.
Journal of Experimental Medicine, Rockefeller University Press vol. 212 (10), 1551-1569.  
24-08-2015
Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia
Hopcroft LEM, Calderhead B, Gallipoli P
In Systems Genetics, Cambridge University Press (Cup) 161-190.  
02-07-2015
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
Gallipoli P, Giotopoulos G, Huntly BJP
Therapeutic Advances in Hematology, Sage Publications vol. 6 (3), 103-119.  
27-04-2015
The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia
Giotopoulos G, Chan W-I, Horton SJ, Ruau D, Gallipoli P, Fowler A, Crawley C, Papaemmanuil E et al.
Oncogene, Springer Nature vol. 35 (3), 279-289.  
20-04-2015
SALVAGE THERAPY WITH BORTEZOMIB AND DEXAMETHASONE IN VERY ELDERLY PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Castelli R, Pantaleo G, Gallipoli P, Arquati M, Wu MA, Deliliers GL
 
01-01-2015

2014

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheadon H, Whetton AD, Jørgensen HG, Bhatia R et al.
Blood, American Society of Hematology vol. 124 (9), 1492-1501.  
23-06-2014
Thrombosis and Hemostatic Abnormalities in Hematological Malignancies
Colombo R, Gallipoli P, Castelli R
Clinical Lymphoma Myeloma & Leukemia, Elsevier vol. 14 (6), 441-450.  
11-06-2014
Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function
Castelli R, Deliliers GL, Colombo R, Moreo G, Gallipoli P, Pantaleo G
Annals of Hematology, Springer Nature vol. 93 (9), 1523-1529.  
08-04-2014
BIOSIMILAR EPOETIN IN ELDERLY PATIENTS WITH LOW-RISK/INTERMEDIATE 1 MYELODYSPLASTIC SYNDROMES IMPROVES ANEMIA, QUALITY OF LIFE AND BRAIN FUNCTION
Castelli R, Deliliers GL, Gallipoli P
 
01-01-2014

2013

Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor
Scott MT, Korfi K, Gallipoli P, Saffrey P, Jorgensen H, Cruz M, Hamilton A, Normant E
 
15-11-2013
The Epigenetic Regulators CBP and p300 Facilitate Leukemogenesis and Represent Therapeutic Targets In Acute Myeloid Leukemia (AML)
Giotopoulos G, Chan W-I, Gallipoli P, Fowler A, Göttgens B, Van Deursen J
Blood, American Society of Hematology vol. 122 (21) 
15-11-2013
Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation
Gallipoli P, Pellicano F, Morrison H, Laidlaw K, Allan EK, Bhatia R, Copland M, Jørgensen HG et al.
Blood, American Society of Hematology vol. 122 (19), 3335-3339.  
16-09-2013
Safety and efficacy of pulsed imatinib with or without G‐CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow‐up
Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L et al.
British Journal of Haematology, Wiley vol. 163 (5), 674-676.  
19-08-2013
Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex
Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H et al.
Journal of The National Cancer Institute, Oxford University Press (Oup) vol. 105 (6), 405-423.  
27-02-2013
Neutrophil‐specific granule deficiency
McIlwaine L, Parker A, Sandilands G
British Journal of Haematology, Wiley vol. 160 (6), 735-735.  
08-01-2013

2012

1009 Targeting Chronic Myeloid Leukemia Stem/progenitor Cells by Effective Inhibition of a Novel AHI-1-BCR-ABL-JAK2 Interaction Complex
Jiang X, Chen M, Gallipoli P, Lai D, Turhan A
 
01-07-2012
Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro
Shah M, Gallipoli P, Lyons J, Holyoake T, Jørgensen H
Blood Cells Molecules and Diseases, Elsevier vol. 48 (3), 199-201.  
09-02-2012
Modulation of TGF-β1 induced quiescence to selectively eradicate chronic myeloid leukaemia stem cells
Gallipoli P, Holyoake T
 
01-01-2012

2011

Hurdles Toward a Cure for CML: The CML Stem Cell
Gallipoli P, Abraham SA, Holyoake TL
Hematology/Oncology Clinics of North America, Elsevier vol. 25 (5), 951-966.  
01-10-2011
Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study
Gallipoli P, Shepherd P, Irvine D, Drummond M, Holyoake T
British Journal of Haematology, Wiley vol. 155 (1), 128-130.  
22-04-2011
TARGETING A NOVEL AHI-1-BCR-ABL-JAK2 INTERACTION COMPLEX BY COMBINATION TREATMENT WITH ABL AND JAK2 INHIBITORS IS EFFECTIVE AGAINST CML PATIENTS'S LEUKEMIC STEM/PROGENITOR CELLS IN VITRO AND IN VIVO
Chen M, DeGeer D, Sloma I, Chan M, Lai D, Jorgensen H, Lambie K, Nakamoto H et al.
 
01-01-2011

2010

Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells.
DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H et al.
Blood, American Society of Hematology vol. 116 (21) 
19-11-2010
RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS AND OUTCOME IN AN IMATINIB TREATED CML POPULATION FROM WEST OF SCOTLAND AND LOTHIAN
Gallipoli P, Shepherd P, Drummond M
 
15-06-2010
Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells
DeGeer D, Gallipoli P, Chen M, Sloma I, Jorgensen H, Forrest D, Lambie K, Nakamoto H et al.
 
01-01-2010
A Review of Lymphoma in Non-transplant Patients on Immunosuppressive Therapy
O'Mahony O, McKay P, Gallipoli P
 
01-01-2010
RETROSPECTIVE ANALYSIS OF PROGNOSTIC FACTORS AND OUTCOME IN AN IMATINIB TREATED CML POPULATION FROM WEST OF SCOTLAND AND LOTHIAN
Gallipoli P, Shepherd P, Mitchell L
 
01-01-2010
JAK2 is a relevant target in chronic myeloid leukaemia
Leitch C, Shah M, Gallipoli P, Zhou P, Yule M
 
01-01-2010
Imatinib efficacy and tolerability in a 'real world' CML population study: Results from a West of Scotland and Lothian retrospective survey
Gallipoli P, Shepherd P, Eynaud P, Hughes M, Laird J, Rhodes S, Sefcick A, Drummond M
 
01-01-2010

2009

Targeted therapy in haematological malignancies
Hamilton A, Gallipoli P, Nicholson E, Holyoake TL
The Journal of Pathology, Wiley vol. 220 (4), 404-418.  
29-12-2009
The evolving management of a rare lymphoproliferative disorder–T‐cell prolymphocytic leukemia
Gallipoli P, Clark A
American Journal of Hematology, Wiley vol. 84 (11), 750-753.  
27-08-2009
Multiple splenic calcifications
Fyfe AJ, Gallipoli P
British Journal of Haematology, Wiley vol. 144 (6), 808-808.  
19-02-2009
Hemophagocytosis and relapsed peripheral T‐cell lymphoma
Gallipoli P, Drummond M
European Journal of Haematology, Wiley vol. 82 (3), 246-246.  
27-01-2009
Pseudotumour cerebri as a manageable side effect of prolonged all‐trans retinoic acid therapy in an adult patient with acute promyelocytic leukaemia
Gallipoli P, Drummond M
European Journal of Haematology, Wiley vol. 82 (3), 242-243.  
27-01-2009

2008

Cortical blindness due to sagittal sinus thrombosis in acute lymphoblastic leukaemia
Gallipoli P, Tang A
British Journal of Haematology, Wiley vol. 145 (3), 270-270.  
05-11-2008
EXPERIENCE OF EXTRANODAL NK/T CELL LYMPHOMAS IN THE WEST OF SCOTLAND
Gallipoli P, McKay P, Gangopadhyay M
 
27-06-2008
EXPERIENCE OF EXTRANODAL NK/T CELL LYMPHOMAS IN THE WEST OF SCOTLAND
Gallipoli P, Jackson B, Leach M
 
01-01-2008

2007

Gingival infiltration in acute monoblastic leukaemia
Gallipoli P
British Dental Journal, Springer Nature vol. 203 (9), 507-509.  
01-11-2007
A case of chronic eosinophilic pneumonia
Gallipoli P
The Journal of The Royal College of Physicians of Edinburgh, Sage Publications vol. 37 (3), 207-209.  
01-09-2007
Off-label use of rFVIIa and its clinical effectiveness: results from a Scottish national audit
Gallipoli P, Robertson M
 
01-01-2007
Risk factors, management and consequences of rhodoturula infections in immunocompromised haematology patients
Gallipoli P, Jones B, McQuaker IG
 
01-01-2007
Hickman line removal is succesfull in treating most of the septic episodes secondary to rhodoturula fungaemia in immunocompromised haemato-oncology patients
Gallipoli P, Jones B, McQuaker IG
 
01-01-2007
Off-label use of rFVIIa and its clinical effectiveness: Results from a Scottish national audit
Gallipoli P, Robertson M
 
01-01-2007

2006

Slate grey pigmentation due to minocycline therapy
Gallipoli P
The Journal of The Royal College of Physicians of Edinburgh, Sage Publications vol. 36 (4), 306-307.  
01-12-2006

2005

Assessment of physical activity in an outpatient obesity clinic in southern Italy: Results from a standardized questionnaire
Finelli C, Gallipoli P, Celentano E, Cacace G, Saldalamacchia G, De Caprio C
Nutrition Metabolism and Cardiovascular Diseases, Elsevier vol. 16 (3), 168-173.  
06-10-2005

2002

Medical education: Britain versus Italy
Gallipoli P
The Bmj, Bmj vol. 324 (Suppl S2) 
01-02-2002
Glasgow: a very interesting place
Gallipoli P
The Bmj, Bmj vol. 324 (Suppl S2) 
01-02-2002

1992

Functional expression and CNS distribution of a β-alanine-sensitive neuronal GABA transporter
Clark JA, Deutch AY, Gallipoli PZ, Amara SG
Neuron, Elsevier vol. 9 (2), 337-348.  
01-08-1992

Mutational synergy coordinately remodels chromatin accessibility, enhancer landscape and 3-Dimensional DNA topology to alter gene expression during leukemia induction

In Biorxiv 
Mannose metabolism inhibition sensitizes acute myeloid leukemia cells to cytarabine and FLT3 inhibitor therapy by modulating fatty acid metabolism to drive ferroptotic cell death
Woodley K, Dillingh LS, Giotopoulos G, Madrigal P, Rattigan KM, Philippe C, Dembitz V, Magee AMS et al.
In Biorxiv 
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 co-activation

In Biorxiv 

Grants

solid heart iconGrants of specific relevance to Predictive in vitro Models
bullet iconValidation of combination therapies targeting fatty acid biosynthesis in acute myeloid leukaemia
Paolo Gallipoli
£7,000 Barts and the London Charity
04-11-2024 - 03-11-2025
bullet iconOptimising therapies targeting fatty acid desaturation in AML
Paolo Gallipoli
£94,540 EHA European Hematology Association
01-10-2024 - 30-09-2026
bullet iconDISSECTING THE ROLE OF MANNOSE METABOLISM IN LEUKEMIA AND NORMAL STEM CELL FUNCTION
Paolo Gallipoli
£320,237 Barts and the London Charity
12-06-2023 - 11-06-2026
bullet iconIdentification and characterisation of metabolic pathways as determinants of drug resistance in acute myeloid leukaemia
Paolo Gallipoli
£1,412,196 Cancer Research UK
01-10-2019 - 30-09-2026

bullet iconMechanisms of anti-leukemic effects of Stearoyl-CoA desaturase (SCD) inhibition
Vilma Dembitz and Paolo Gallipoli
£16,500 Lady Tata Memorial Trust
01-10-2022 - 30-09-2023
bullet iconASH Global Research Award Budget 2018-20
Paolo Gallipoli
£32,905 ASH American Society of Hematology
01-10-2019 - 31-01-2020